Carmell Research Development vs Interest Expense Analysis

CTCXW Stock

0.06 0 1.96%

Carmell Therapeutics financial indicator trend analysis is way more than just evaluating Carmell Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Carmell Therapeutics is a good investment. Please check the relationship between Carmell Therapeutics Research Development and its Interest Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Research Development vs Interest Expense

Research Development vs Interest Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Carmell Therapeutics Research Development account and Interest Expense. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Carmell Therapeutics' Research Development and Interest Expense is -0.43. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Carmell Therapeutics, assuming nothing else is changed. The correlation between historical values of Carmell Therapeutics' Research Development and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Carmell Therapeutics are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Research Development i.e., Carmell Therapeutics' Research Development and Interest Expense go up and down completely randomly.

Correlation Coefficient

-0.43

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Research Development

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Most indicators from Carmell Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Carmell Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Selling General Administrative is likely to drop to about 2.5 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year

	2010	2022	2023	2024 (projected)
Interest Expense	2.5M	3.7M	889.3K	844.9K
Depreciation And Amortization	242.1K	242.6K	124.8K	162.5K

Interest Expense Depreciation And Amortization

Carmell Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock
Total Assets		-0.8	0.99	0.81	0.99	-0.9	0.35	-0.91	-0.97	0.89	1.0	-0.9	0.92	-0.95	1.0	-0.98	-0.79	-0.94	1.0	1.0	0.79	0.98	-0.84	-0.85	1.0	-0.77
Short Long Term Debt Total	-0.8		-0.73	-0.54	-0.74	0.95	0.19	0.97	0.92	-0.95	-0.82	0.95	-0.71	0.71	-0.82	0.82	0.29	0.92	-0.8	-0.81	-0.98	-0.67	0.77	0.99	-0.8	0.99
Other Current Liab	0.99	-0.73		0.84	1.0	-0.84	0.46	-0.86	-0.93	0.84	0.99	-0.84	0.93	-0.95	0.99	-0.97	-0.86	-0.9	0.99	0.99	0.72	1.0	-0.8	-0.79	0.99	-0.69
Total Current Liabilities	0.81	-0.54	0.84		0.85	-0.53	0.71	-0.62	-0.68	0.78	0.8	-0.54	0.97	-0.62	0.8	-0.89	-0.86	-0.6	0.81	0.81	0.42	0.87	-0.36	-0.53	0.81	-0.42
Total Stockholder Equity	0.99	-0.74	1.0	0.85		-0.84	0.45	-0.86	-0.93	0.85	0.99	-0.85	0.93	-0.94	0.99	-0.98	-0.85	-0.9	0.99	0.99	0.72	1.0	-0.79	-0.79	0.99	-0.7
Property Plant And Equipment Net	-0.9	0.95	-0.84	-0.53	-0.84		0.09	0.99	0.98	-0.9	-0.91	1.0	-0.72	0.89	-0.91	0.86	0.44	0.99	-0.9	-0.9	-0.98	-0.79	0.93	0.99	-0.9	0.96
Current Deferred Revenue	0.35	0.19	0.46	0.71	0.45	0.09		0.03	-0.11	0.12	0.33	0.09	0.56	-0.26	0.33	-0.4	-0.84	-0.01	0.36	0.34	-0.27	0.54	0.1	0.16	0.35	0.29
Net Debt	-0.91	0.97	-0.86	-0.62	-0.86	0.99	0.03		0.99	-0.95	-0.92	0.99	-0.79	0.86	-0.92	0.9	0.47	0.99	-0.91	-0.92	-0.97	-0.81	0.88	0.99	-0.92	0.96
Retained Earnings	-0.97	0.92	-0.93	-0.68	-0.93	0.98	-0.11	0.99		-0.93	-0.97	0.98	-0.83	0.93	-0.97	0.94	0.61	0.99	-0.97	-0.97	-0.92	-0.89	0.9	0.96	-0.97	0.91
Accounts Payable	0.89	-0.95	0.84	0.78	0.85	-0.9	0.12	-0.95	-0.93		0.9	-0.9	0.89	-0.74	0.9	-0.94	-0.51	-0.89	0.89	0.89	0.88	0.81	-0.69	-0.93	0.89	-0.89
Cash	1.0	-0.82	0.99	0.8	0.99	-0.91	0.33	-0.92	-0.97	0.9		-0.91	0.91	-0.95	1.0	-0.98	-0.77	-0.95	1.0	1.0	0.81	0.97	-0.85	-0.87	1.0	-0.79
Non Current Assets Total	-0.9	0.95	-0.84	-0.54	-0.85	1.0	0.09	0.99	0.98	-0.9	-0.91		-0.72	0.89	-0.91	0.86	0.45	0.99	-0.9	-0.9	-0.98	-0.79	0.93	0.99	-0.9	0.96
Non Currrent Assets Other	0.92	-0.71	0.93	0.97	0.93	-0.72	0.56	-0.79	-0.83	0.89	0.91	-0.72		-0.75	0.91	-0.97	-0.82	-0.76	0.92	0.91	0.62	0.93	-0.55	-0.71	0.92	-0.62
Long Term Debt	-0.95	0.71	-0.95	-0.62	-0.94	0.89	-0.26	0.86	0.93	-0.74	-0.95	0.89	-0.75		-0.95	0.87	0.74	0.93	-0.95	-0.95	-0.76	-0.93	0.94	0.8	-0.95	0.73
Cash And Short Term Investments	1.0	-0.82	0.99	0.8	0.99	-0.91	0.33	-0.92	-0.97	0.9	1.0	-0.91	0.91	-0.95		-0.98	-0.77	-0.95	1.0	1.0	0.81	0.97	-0.85	-0.87	1.0	-0.79
Common Stock Shares Outstanding	-0.98	0.82	-0.97	-0.89	-0.98	0.86	-0.4	0.9	0.94	-0.94	-0.98	0.86	-0.97	0.87	-0.98		0.78	0.89	-0.98	-0.98	-0.77	-0.96	0.73	0.84	-0.98	0.76
Non Current Liabilities Total	-0.79	0.29	-0.86	-0.86	-0.85	0.44	-0.84	0.47	0.61	-0.51	-0.77	0.45	-0.82	0.74	-0.77	0.78		0.54	-0.79	-0.78	-0.25	-0.9	0.46	0.35	-0.79	0.22
Capital Lease Obligations	-0.94	0.92	-0.9	-0.6	-0.9	0.99	-0.01	0.99	0.99	-0.89	-0.95	0.99	-0.76	0.93	-0.95	0.89	0.54		-0.94	-0.94	-0.94	-0.85	0.94	0.97	-0.94	0.93
Other Current Assets	1.0	-0.8	0.99	0.81	0.99	-0.9	0.36	-0.91	-0.97	0.89	1.0	-0.9	0.92	-0.95	1.0	-0.98	-0.79	-0.94		1.0	0.79	0.98	-0.84	-0.85	1.0	-0.77
Other Stockholder Equity	1.0	-0.81	0.99	0.81	0.99	-0.9	0.34	-0.92	-0.97	0.89	1.0	-0.9	0.91	-0.95	1.0	-0.98	-0.78	-0.94	1.0		0.8	0.98	-0.84	-0.86	1.0	-0.78
Total Liab	0.79	-0.98	0.72	0.42	0.72	-0.98	-0.27	-0.97	-0.92	0.88	0.81	-0.98	0.62	-0.76	0.81	-0.77	-0.25	-0.94	0.79	0.8		0.65	-0.87	-0.99	0.8	-1.0
Net Invested Capital	0.98	-0.67	1.0	0.87	1.0	-0.79	0.54	-0.81	-0.89	0.81	0.97	-0.79	0.93	-0.93	0.97	-0.96	-0.9	-0.85	0.98	0.98	0.65		-0.75	-0.73	0.98	-0.62
Property Plant And Equipment Gross	-0.84	0.77	-0.8	-0.36	-0.79	0.93	0.1	0.88	0.9	-0.69	-0.85	0.93	-0.55	0.94	-0.85	0.73	0.46	0.94	-0.84	-0.84	-0.87	-0.75		0.87	-0.84	0.83
Short Long Term Debt	-0.85	0.99	-0.79	-0.53	-0.79	0.99	0.16	0.99	0.96	-0.93	-0.87	0.99	-0.71	0.8	-0.87	0.84	0.35	0.97	-0.85	-0.86	-0.99	-0.73	0.87		-0.85	0.99
Total Current Assets	1.0	-0.8	0.99	0.81	0.99	-0.9	0.35	-0.92	-0.97	0.89	1.0	-0.9	0.92	-0.95	1.0	-0.98	-0.79	-0.94	1.0	1.0	0.8	0.98	-0.84	-0.85		-0.77
Capital Stock	-0.77	0.99	-0.69	-0.42	-0.7	0.96	0.29	0.96	0.91	-0.89	-0.79	0.96	-0.62	0.73	-0.79	0.76	0.22	0.93	-0.77	-0.78	-1.0	-0.62	0.83	0.99	-0.77

Click cells to compare fundamentals

Carmell Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Carmell Research Development vs Interest Expense Analysis

Research Development vs Interest Expense

Research Development vs Interest Expense Correlation Analysis

Correlation Coefficient

Research Development

Interest Expense

Carmell Therapeutics fundamental ratios Correlations

Carmell Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Carmell Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Total Assets
Other Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Stockholder Equity	+ 1.0	Other Current Liab

Capital Stock	- 1.0	Total Liab
Short Long Term Debt	- 0.99	Total Liab
Total Current Assets	- 0.98	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.98	Common Stock Shares Outstanding
Other Current Assets	- 0.98	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.98	Cash And Short Term Investments